NeoGenomics, Inc. Executive Leadership Team

Douglas VanOort

Chairman & Chief Executive Officer

Mr. VanOort has served as Chairman and Chief Executive Office since joining NeoGenomics in March 2009. Prior to that, he held executive leadership positions with several Fortune 500 firms and rapidly-growing ventures during his 30-year career. He spent over 10 years in health-care services, first as Executive Vice President and Chief Financial Officer of Corning Life Sciences, Inc. and then as Senior Vice President, Operations at Quest Diagnostics, Inc.

At Corning Life Sciences, he helped build and engineer the spinoff of two leading publically-traded NYSE life-science companies, Quest Diagnostics, Inc. and Covance, Inc, ultimately joining Quest at the time of the spin-off. During his tenure with Corning Life Sciences and then Quest, he was part of the team that successfully transformed the company into the largest independent clinical laboratory testing company in the United States, growing it from approximately $500 million in revenue in 1989 to approximately $1.5 billion in revenue in 1998.

During the past 10 years, Mr. VanOort founded, invested in, and built businesses in a variety of industries. In addition, he has served as an Operating Partner at Summer Street Capital Partners since 2003. Mr. VanOort received his B.S. in Accounting from Bentley University.

Maher Albitar, M.D.

Chief Medical Officer & Director of Research and Development

Dr. Albitar joined NeoGenomics in January 2012 to serve as Chief Medical Officer and Director of Research and Development. Prior to joining NeoGenomics, Dr. Albitar served as the Chief Medical Officer of Health Discovery Corporation. Before HDC, he was the Medical Director for Hematopathology and Oncology and Chief of Research and Development for Quest Diagnostics Nichols Institute, and prior to that he held various faculty positions at The University of Texas MD Anderson Cancer Center.

Dr. Albitar attended medical school at Damascus Medical School, completed his Anatomic Pathology and Clinical Pathology Residency at Brown University, and completed a Hematopathology Fellowship as well as a post-doctoral training in Genetics at the Howard Hughes Medical Institute at the University of Pennsylvania. He holds numerous patents and has authored more than 300 peer-reviewed papers, book chapters, and review articles.

Robert Gasparini, M.S., CLSp(CG), CLDir

Chief Science Officer

Mr. Gasparini has served as Chief Science Officer and a member of our Board of Directors since joining NeoGenomics in January 2005. He also held the position of President from January 2005 until April 2011. Prior to joining NeoGenomics, Mr. Gasparini was Director of the Genetics Division for US Labs, and prior to that was the Molecular Marketing Manager for Ventana Medical Systems.

Prior to Ventana, Mr. Gasparini was the Assistant Director of the Cytogenetics Laboratory for the Prenatal Diagnostic Center an affiliate of Mass General Hospital. While at the Prenatal Diagnostic Center, Mr. Gasparini was also an Adjunct Professor at Harvard University.

Mr. Gasparini is a licensed Clinical Laboratory Director and an accomplished author in the field of Cytogenetics and Fluorescence In-Situ Hybridization (FISH) testing. He received his B.S. in Biological Sciences from the University of Connecticut and his Master of Health Science from Quinnipiac University in Laboratory Administration.

George Cardoza

Chief Financial Officer

Mr. Cardoza has served as Chief Financial Officer since joining NeoGenomics in November 2009. Prior to joining NeoGenomics, he served as Chief Financial Officer of Protocol Global Solutions, Inc., a privately held international marketing company from March 2008 until November 2009. From March 2006 to March 2008, Mr. Cardoza served as Controller of Protocol Global Solutions. From April 1991 to March 2006, Mr. Cardoza was employed by Quest Diagnostics Inc., a diagnostic testing and services company, in a number of positions, including the position of Controller—Central Region from 2001 to March 2006. In his last position at Quest, Mr. Cardoza was responsible for overseeing all the financial operations of the Central Region, which had revenue of over $1.2 billion in 2006.

Prior to his time with Quest, he worked for Sony Music Entertainment Inc. and the Continental Grain Company in various financial roles. Mr. Cardoza received his B.S. in Finance and Accounting from Syracuse University and received his M.B.A. from Michigan State University.

Steven Jones

Executive Vice President, Finance & Director of Investor Relations

Mr. Jones has served as our Executive Vice President, Finance and Director of Investor Relations since November 2009 and as a member of our Board of Directors since October 2003. From April 2003 until November 2009, he served as our Chief Financial Officer. Prior to that Mr. Jones was chief financial officer at various public and private companies and was a Vice President in the Investment Banking Division of Merrill Lynch & Co.

Mr. Jones is also a Managing Director in Medical Venture Partners, LLC, which serves as the general partner for Aspen Select Healthcare, LP, a large shareholder of the Company. Mr. Jones received his B.S. in Computer Engineering from the University of Michigan and his M.B.A. from the Wharton School of the University of Pennsylvania.

Robert Horel

Vice President, Sales & Marketing

Mr. Horel joined NeoGenomics in December 2006 and has served as Vice President, Sales and Marketing since May 2011. From December 2006 until May 2011, he served as the Regional Sales Director for NeoGenomics’ Southeastern Region. Prior to joining NeoGenomics, Mr. Horel held sales and marketing positions of increasing prominence with Ventana Medical Systems, a manufacturer of certain medical tests and instruments; US Labs, an anatomic pathology and genetic testing laboratory; and Radiometer America, a medical testing and instrumentation company.

Mr. Horel graduated from the United States Naval Academy, earning a B.S. with Distinction in Mechanical Engineering, and he served as a pilot in the US Navy before beginning his business career in 1998.